Resistant hypertension: Trials and tribulations

Marc J. George; Daniel J.B. Marks; Tamer Rezk; Ross Breckenridge; Reecha Sofat; John Martin; Raymond Macallister; Rhian M. Touyz; Jan A. Staessen; Michael Bursztyn; David Lappin; Mohammed Barigou; Aroon Hingorani

doi:10.1161/HYPERTENSIONAHA.118.10864

Resistant hypertension: Trials and tribulations

Marc J. George, Daniel J.B. Marks, Tamer Rezk, Ross Breckenridge, Reecha Sofat, John Martin, Raymond Macallister, Rhian M. Touyz, Jan A. Staessen, Michael Bursztyn, David Lappin, Mohammed Barigou, Aroon Hingorani

Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review

Abstract

In summary, I have presented a case of a patient with true resistant hypertension. We have discussed how to optimize her medical management as well as investigations of secondary causes, particularly primary aldosteronism. We have also discussed the evidence base for RDN and the deficiencies of the original SYMPLICITY trials. Several lessons have been learned about the design and conduct of clinical trials in this field that are now being implemented to definitively assess the efficacy of this approach.

Original language	English
Pages (from-to)	772-780
Number of pages	9
Journal	Hypertension
Volume	71
Issue number	5
DOIs	https://doi.org/10.1161/HYPERTENSIONAHA.118.10864
Publication status	Published - 1 May 2018
Externally published	Yes

Access to Document

10.1161/HYPERTENSIONAHA.118.10864

Cite this

@article{5d8f58528c354beead075daf3e66d584,

title = "Resistant hypertension: Trials and tribulations",

abstract = "In summary, I have presented a case of a patient with true resistant hypertension. We have discussed how to optimize her medical management as well as investigations of secondary causes, particularly primary aldosteronism. We have also discussed the evidence base for RDN and the deficiencies of the original SYMPLICITY trials. Several lessons have been learned about the design and conduct of clinical trials in this field that are now being implemented to definitively assess the efficacy of this approach.",

author = "George, \{Marc J.\} and Marks, \{Daniel J.B.\} and Tamer Rezk and Ross Breckenridge and Reecha Sofat and John Martin and Raymond Macallister and Touyz, \{Rhian M.\} and Staessen, \{Jan A.\} and Michael Bursztyn and David Lappin and Mohammed Barigou and Aroon Hingorani",

note = "Publisher Copyright: {\textcopyright} 2018 American Heart Association, Inc.",

year = "2018",

month = may,

day = "1",

doi = "10.1161/HYPERTENSIONAHA.118.10864",

language = "English",

volume = "71",

pages = "772--780",

journal = "Hypertension",

issn = "0194-911X",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Resistant hypertension

T2 - Trials and tribulations

AU - George, Marc J.

AU - Marks, Daniel J.B.

AU - Rezk, Tamer

AU - Breckenridge, Ross

AU - Sofat, Reecha

AU - Martin, John

AU - Macallister, Raymond

AU - Touyz, Rhian M.

AU - Staessen, Jan A.

AU - Bursztyn, Michael

AU - Lappin, David

AU - Barigou, Mohammed

AU - Hingorani, Aroon

PY - 2018/5/1

Y1 - 2018/5/1

N2 - In summary, I have presented a case of a patient with true resistant hypertension. We have discussed how to optimize her medical management as well as investigations of secondary causes, particularly primary aldosteronism. We have also discussed the evidence base for RDN and the deficiencies of the original SYMPLICITY trials. Several lessons have been learned about the design and conduct of clinical trials in this field that are now being implemented to definitively assess the efficacy of this approach.

AB - In summary, I have presented a case of a patient with true resistant hypertension. We have discussed how to optimize her medical management as well as investigations of secondary causes, particularly primary aldosteronism. We have also discussed the evidence base for RDN and the deficiencies of the original SYMPLICITY trials. Several lessons have been learned about the design and conduct of clinical trials in this field that are now being implemented to definitively assess the efficacy of this approach.

UR - https://www.scopus.com/pages/publications/85054131223

U2 - 10.1161/HYPERTENSIONAHA.118.10864

DO - 10.1161/HYPERTENSIONAHA.118.10864

M3 - Article

C2 - 29610269

AN - SCOPUS:85054131223

SN - 0194-911X

VL - 71

SP - 772

EP - 780

JO - Hypertension

JF - Hypertension

IS - 5

ER -

Resistant hypertension: Trials and tribulations

Abstract

Access to Document

Other files and links

Fingerprint

Cite this